Sign Up Today and Learn More About Mammoth Biosciences Stock
Invest in or calculate the value of your shares in Mammoth Biosciences or other pre-IPO companies through EquityZen's platform.
Mammoth Biosciences Stock (MABI)
Mammoth Biosciences leverages its proprietary ultra-compact CRISPR platform for gene editing therapies. They focus on in vivo delivery, aiming for long-term cures for life-threatening diseases. Their protein discovery pipeline seeks novel CRISPR systems with functionalities beyond double-stranded breaks, including base and epigenetic editing. Co-founded by CRISPR pioneer Jennifer Doudna.
Mammoth Biosciences develops novel CRISPR applications for disease detection, research, agriculture, biodefense, and more.
About Mammoth Biosciences Stock
Founded
2017
Headquarters
San Francisco, CA, US
Total Funding
365M
Industries
Science and Engineering, Health Care, Biotechnology
Mammoth Biosciences is a developer of a CRISPR platform for diagnostic, genome editing, and protein discovery applications. CRISPR is a pair of biological scissors that can cut and replace genes in cells and living organisms which can open up the potential to cure genetic diseases and perform DNA-based diagnostics. Mammoth aims to discover new types of CRISPR systems that could be used to solve specific biological problems.
Mammoth Biosciences was founded by Janice Chen in 2017 and is based in San Francisco, California. Notable investors include NFX, Mayfield Fund, and Decheng Capital.
Mammoth Biosciences Press Mentions
Stay in the know about the latest news on Mammoth Biosciences
Mammoth Biosciences Announces Nomination of MB-111 as First Development Candidate and Appoints Genetic Medicines Veteran Bob D. Brown to Board of Directors
morningstar • May 05, 2025
Mammoth Biosciences Announces Nomination of MB-111 as First Development Candidate and Appoints Genetic Medicines Veteran Bob D. Brown to Board of Directors
biospace • May 05, 2025
Mammoth Biosciences Announces Nomination of MB-111 as First Development Candidate and Appoints Genetic Medicines Veteran Bob D. Brown to Board of Directors
businesswire • May 05, 2025
Devices, systems and methods for analysis of nucleic acids
patents • May 04, 2025
Programmable nucleases and methods of use
patents • May 04, 2025
Investors in Mammoth Biosciences
Discover investors in Mammoth Biosciences stock and explore their portfolio companies
Mammoth Biosciences Management
Leadership team at Mammoth Biosciences
Chief Executive Officer
Trevor Martin
Chief Financial Officer
Elaine Sun
Join now and verify your accreditation status to gain access to:
- Mammoth Biosciences Current Valuation
- Mammoth Biosciences Stock Price
- Mammoth Biosciences Management
- Available deals in Mammoth Biosciences and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Mammoth Biosciences Cap Table and Funding History by Share Class and Liquidity Preferences
- Mammoth Biosciences Revenue and Financials
- Mammoth Biosciences Highlights
- Mammoth Biosciences Business Model
- Mammoth Biosciences Risk Factors
- Mammoth Biosciences Research Report from SACRA Research
Mammoth Biosciences Key Facts
• Mammoth Biosciences holds patents and licenses related to CRISPR diagnostics and therapeutics, providing a competitive advantage in the rapidly evolving biotechnology landscape. Strong intellectual property protection allows Mammoth Biosciences to commercialize its innovations effectively and defend its market position against competitors.
• The versatility of CRISPR technology positions Mammoth Biosciences to explore various applications beyond diagnostics, including therapeutics and agriculture. Beyond diagnostics, Mammoth Biosciences is exploring CRISPR-based therapeutics for genetic diseases and cancer treatment.
• The global demand for advanced diagnostic tools continues to grow, driven by increasing healthcare needs and aging populations. Mammoth Biosciences’ CRISPR-based diagnostics offer potential solutions to enhance disease detection, surveillance, and personalized medicine, addressing critical gaps in current healthcare systems.
• Other companies, such as Editas Medicine and CRISPR Therapeutics, are also advancing CRISPR technologies for therapeutic applications and have made significant progress in clinical trials. These competitors have substantial financial resources, research capabilities, and strategic partnerships that could pose competitive threats to Mammoth Biosciences.
• Successfully commercializing new technologies and achieving widespread market adoption are critical challenges for biotechnology companies. Despite promising advancements in CRISPR diagnostics, Mammoth Biosciences faces risks related to market acceptance, pricing pressures, and competition from alternative diagnostic methods.
• Regulatory approvals for new diagnostics and therapeutics can be lengthy, costly, and uncertain, potentially delaying commercialization timelines and impacting revenue generation. Changes in regulatory frameworks or public perception of gene editing could also affect market acceptance and adoption of Mammoth Biosciences’ products.
Trading Mammoth Biosciences Stock
How to invest in Mammoth Biosciences stock?
Accredited investors can buy pre-IPO stock in companies like Mammoth Biosciences through EquityZen funds. These investments are made available by existing Mammoth Biosciences shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Mammoth Biosciences stock?
Shareholders can sell their Mammoth Biosciences stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
